SATB1 and colorectal carcinoma: Statistical analysis revealed that the SATB1 immunoreactivity was significantly higher in cancer cells of all the analyzed CRC cases as compared to its expression noted in cells of the unchanged mucosa (IRS 4.36 ± 0.38 vs. 1.74 ± 0.31, respectively; P < 0.0001; Fig. 4a).